Form 4 for ANIX Anixa Biosciences Inc
Accepted 2021-11-02 00:00:00 ET · period of report 2021-10-29 · accession 0001493152-21-026933 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-02 | 2021-10-29 | ANIX | Catelani Michael | COO, CFO | J - Other | $4.04 | +743 | 10.1K | +8% | +$3,002 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-29 | J | A | 743 | $4.04 | 10,126 | D | — | — | (F2) In accordance with the Plan, the shares were purchased based on 85% of the closing price of Anixa Biosciences, Inc. common stock on May 3, 2021. |